Open-Label Study With Rilpivirine in Treatment-naïve Indian Subjects With HIV-1 Infection to Determine Safety and Efficacy
Phase of Trial: Phase III
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Rilpivirine (Primary) ; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms RISE
- Sponsors Johnson & Johnson
- 12 Oct 2018 Planned End Date changed from 30 Jul 2020 to 31 Aug 2020.
- 12 Oct 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Planned End Date changed from 15 Jul 2020 to 30 Jul 2020.